IGI Logo

We hosted Mr. Nikhil Chopra (CEO), Mr. Kunal Khanna (President Transformation) and Mr. Jason D’Souza (IR) for the Healthcare & Chemicals Day on August 17th , 2021.

Key MeetingTakeaways Domestic business:

* Expects Rantac and Metrogyl demand to normalise and revert to mean growth trajectory Q2FY22 onwards.

* Focussed on brand extensions for both Cilicar and Nicardia with the intent of launching products at the right time.

* Expects 4-6 % incremental volume growth from newer therapies.

Trade generics business:

* Targeting tier 2 and tier 3 cities however revenue contribution will be in single digit.

* Business is margin accretive as no incremental capital is required (channel-driven market).

Export business:

* Pricing pressure is restricted to few molecules which previously had disruptions. Portfolio pricing pressure is manageable.

* Russia as a geography is absolute EBITDA accretive and expects double-digit revenue growth to international business.

* No synergy between US and India portfolio. US strategy driven by competitive landscape and not the portfolio breadth.

* Performed extremely well in US and South Africa market in Q1FY22.

Selectively increasing run rate of ANDAs in US. Lozenges:

* JB’s 3-year plan includes doubling of the business (both in terms of value and volume) driven by products in new categories such as immunity and strengthening of R&D in lozenges.

* Added one additional anchor client (OTC pharma space); one anchor client already on board from the APAC region.

* Launched lozenges for dry mouth and nicotine/sugar free lozenges in the Indian market.

To Read Complete Report & Disclaimer Click Here

Please refer disclaimer at  https://www.mnclgroup.com/disclaimer

SEBI Registration Number : INZ000043833

Above views are of the author and not of the website kindly read disclaimer